Transthyretin amyloidosis in spinal canal stenosis: A systematic review
Journal of Orthopaedics · 2024-07 · 53 · 133-139
DOI: 10.1016/j.jor.2024.02.047 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Orthopaedics, 2024-07. Verfasst von Zachary J Moore und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Utah School of Medicine, 30 N 1900 E, Salt Lake City, UT, 84132, United States. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
We systematically review literature regarding the contribution of transthyretin amyloidosis to spinal stenosis. Amyloidosis is a protein misfolding condition that causes systemic deposition of amyloid and commonly leads to heart failure and nephropathy. A growing body of literature suggests that amyloid deposits within the ligamentum flavum are frequently associated with spinal stenosis with subsequent myelopathy. Our search identified 67 publications from the PubMed database for literature review. After evaluating the inclusion and exclusion criteria, a total of 18 articles were included in the review. Each article was evaluated for country, study type, sample size, amyloidosis subtype, spinal level, systemic symptoms, treatment, patient outcome, and conclusions. Many studies concluded that lumbar ligamentum flavum hypertrophy is more severe in patients with amyloidosis due to associated amyloid deposition. Additionally, patients with systemic amyloidosis are more likely to have recurrence of spinal stenosis. Multiple studies encourage routine screening be performed on spinal stenosis patients to target those needing cardiac surveillance. Amyloid deposition is frequently associated with spinal stenosis, and its presence may provide an earlier opportunity to diagnose or predict systemic amyloidosis. Surgeons should consider obtaining intraoperative biopsy to identify amyloidosis and inform screening postoperatively. Finally, physicians should be aware of this association and counsel patients accordingly on the risks and treatment options available for amyloidosis.
Autor:innen und Institutionen
- University of Utah School of Medicine, 30 N 1900 E, Salt Lake City, UT, 84132, United States.
- University of Utah Department of Orthopaedic Surgery, 590 Wakara Way, Salt Lake City, UT, 84108, United States.
Zitieren
APA
Moore, Z. J., Rizkalla, J. M., Weiner, J., Lawrence, B., Spina, N., Spiker, R., Brodke, D., & Karamian, B. (2024). Transthyretin amyloidosis in spinal canal stenosis: A systematic review. Journal of Orthopaedics, 53, 133-139. https://doi.org/10.1016/j.jor.2024.02.047
Vancouver
Moore ZJ, Rizkalla JM, Weiner J, Lawrence B, Spina N, Spiker R, et al. Transthyretin amyloidosis in spinal canal stenosis: A systematic review. Journal of Orthopaedics. 2024;53:133-139. doi:10.1016/j.jor.2024.02.047
BibTeX
@article{Moore2024,
author = {Moore, Zachary J and Rizkalla, James M and Weiner, Joseph and Lawrence, Brandon and Spina, Nicolas and Spiker, Ryan and Brodke, Darrel and Karamian, Brian},
title = {Transthyretin amyloidosis in spinal canal stenosis: A systematic review},
journal = {Journal of Orthopaedics},
year = {2024},
volume = {53},
pages = {133--139},
doi = {10.1016/j.jor.2024.02.047}
}
EUVIMED